Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cell replacement therapy for type 1 diabetes.

Shimon Efrat1

  • 1Dept of Human Genetics and Molecular Medicine, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel. sefrat@post.tau.ac.il

Trends in Molecular Medicine
|July 13, 2002
PubMed
Summary

Cell replacement therapy offers a potential cure for type 1 diabetes by generating new insulin-producing beta cells. Future strategies focus on stem cells and protecting these cells from autoimmune attack.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epigenetic Memory: Lessons From iPS Cells Derived From Human β Cells.

Frontiers in endocrinology·2021
Same author

Beta-Cell Dedifferentiation in Type 2 Diabetes: Concise Review.

Stem cells (Dayton, Ohio)·2019
Same author

Genes Associated with Pancreas Development and Function Maintain Open Chromatin in iPSCs Generated from Human Pancreatic Beta Cells.

Stem cell reports·2017
Same author

Redifferentiation of expanded human islet β cells by inhibition of ARX.

Scientific reports·2016
Same author

TGFβ Pathway Inhibition Redifferentiates Human Pancreatic Islet β Cells Expanded In Vitro.

PloS one·2015
Same author

Inhibition of ZEB1 expression induces redifferentiation of adult human β cells expanded in vitro.

Scientific reports·2015

Area of Science:

  • Endocrinology
  • Regenerative Medicine
  • Immunology

Background:

  • Type 1 diabetes is characterized by the destruction of insulin-producing pancreatic islet beta cells.
  • Current islet transplantation relies on scarce human donors, necessitating alternative cell sources.
  • Recurring autoimmunity poses a significant challenge to the long-term success of beta cell replacement therapies.

Purpose of the Study:

  • To explore alternative strategies for generating insulin-producing beta cells for type 1 diabetes treatment.
  • To investigate methods for protecting transplanted or engineered beta cells from autoimmune destruction.
  • To discuss the potential for widespread cell replacement therapy for type 1 diabetes.

Main Methods:

  • Exploring reversible immortalization of differentiated beta cells.
  • Generating insulin-producing cells from embryonic and adult stem cells.
  • Investigating progenitor-cell fate manipulation for beta cell generation.
  • Considering immune protection strategies like tolerization, encapsulation, and genetic engineering.

Main Results:

  • Two primary approaches for generating beta cells are proposed: expanding existing cells and creating new ones from stem cells.
  • Insights into endocrine pancreas development may enable manipulation of progenitor cells.
  • Several immune protection strategies are identified as crucial for therapeutic success.

Conclusions:

  • Cell replacement therapy holds promise for type 1 diabetes, offering a potential cure.
  • Generating functional beta cells from alternative sources and protecting them from autoimmunity are key challenges.
  • Successful implementation of these strategies could lead to widespread cell replacement therapy for type 1 diabetes.

Related Experiment Videos